Lockheed Martin stock near $500 premarket as Venezuela shock and space-deal chatter refocus defense trade

Lockheed Martin stock near $500 premarket as Venezuela shock and space-deal chatter refocus defense trade

NEW YORK, Jan 5, 2026, 05:43 ET — Premarket

  • Lockheed Martin was little changed in premarket trading, holding near $497 after Friday’s jump.
  • A Reuters report on L3Harris’ space propulsion stake sale put United Launch Alliance — co-owned by Lockheed — back on traders’ radar.
  • Investors are also watching Friday’s U.S. jobs report and Lockheed’s late-January earnings for the next directional cue.

Lockheed Martin (LMT.N) shares were little changed at $497.07 in premarket trading on Monday, holding near last session’s close after the stock rose about 2.8% on Friday.

Defense names drew fresh attention after U.S. President Donald Trump said the United States captured Venezuelan President Nicolas Maduro after strikes over the weekend, a flashpoint investors said could reshape how markets price geopolitical risk. “We’re being reminded that geopolitical risks are much larger than some number cast on imports,” said Vishnu Varathan, head of macro research for Asia ex-Japan at Mizuho Securities in Singapore. Reuters

Separately, Reuters reported L3Harris Technologies is in advanced talks to sell a 60% stake in its Commercial Aviation Solutions business to private equity firm AE Industrial Partners at an enterprise value of about $845 million. Enterprise value is a common deal yardstick that includes debt, giving a fuller picture of what a buyer is paying. Reuters

The portfolio includes the RL-10 rocket engine used in United Launch Alliance’s Vulcan launcher, Reuters said. ULA is a joint venture owned by Boeing and Lockheed, and the report said the business also has ties to the Pentagon’s emerging “Golden Dome” missile-defense effort — a plan for a layered shield designed to detect and intercept missiles. Reuters

For Lockheed shareholders, the swirl matters because space and missile-defense programs sit at the intersection of geopolitics, budget priorities and industrial capacity. Any shift in supply chains or funding can ripple across primes and their partners.

Technically, traders have been watching the stock’s approach to $500, a round-number level that can act as a psychological hurdle. Barchart data put the first resistance point near $503.97 and first support around $483.35, with the 52-week high at $516.00. Barchart

The next company catalyst is earnings. TipRanks lists Lockheed’s next report for Jan. 27, before the open, with an EPS forecast of about $6.49 for the quarter.

Macro events may set the tone before then, starting with the U.S. employment report for December scheduled for Jan. 9 and the December consumer price index due Jan. 13. The Federal Reserve’s next policy meeting is set for Jan. 27-28.

Lockheed competes with peers such as RTX and Northrop Grumman across missiles, sensors and other defense programs, while its ULA partnership links it to developments in the U.S. launch market. Moves across the group often track shifts in perceived geopolitical risk and expectations for defense budgets.

But the bid for defense stocks can fade if markets decide the Venezuela shock stays contained or if budget politics swing back toward restraint. Deal headlines can also disappoint: a slower timeline or changed terms around the L3Harris asset sale would likely cool some of the near-term enthusiasm.

Stock Market Today

  • Intuitive Surgical valuation near fair value after strong run
    January 6, 2026, 8:55 PM EST. Intuitive Surgical (ISRG) appears near its narrative fair value of $596.36, with a last close of $592.85. The gap is small despite a 90-day return of 32.3% and a 5-year TSR of 125.6%. The narrative attributes value to ongoing product innovation-da Vinci 5, integrated force feedback, and AI-driven case insights-that could lift procedure growth, system ASPs, and recurring instrument revenues. Risks include tariff-related margin pressure and tighter hospital budgets in key international markets. The stock's forward P/E at about 76.5x sits well above the Medical Equipment group (≈29.9x) and peers, implying a premium. The question: is that premium justified by the outlook for growth and margins?
AMD stock jumps in premarket as Lisa Su’s CES keynote and key U.S. data come into view
Previous Story

AMD stock jumps in premarket as Lisa Su’s CES keynote and key U.S. data come into view

Marathon Petroleum stock jumps nearly 6% premarket as Venezuela oil bets lift U.S. refiners
Next Story

Marathon Petroleum stock jumps nearly 6% premarket as Venezuela oil bets lift U.S. refiners

Go toTop